Underlying EBITDA as per updated guidance in May, so nothing to see there...
FY19 Outlook seems to be better considering the reduction in operating costs as per planned with a bit more than one third achieved already. Trading outlook as per below seems good too..standalone GP clinics LFL fall in sales seem to have decelerated..
Trading update as at week 6:
• 5.8% Group LFL sales growth
• 6.1% Group Retail LFL sales growth
• 5.2% Australian Vet LFL sales growth including negative LFL sales in standalone GP clinics of 0.5%
• 8.0% Group revenue growth
GXL Price at posting:
$4.23 Sentiment: Buy Disclosure: Held